These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
23. Enzyme-Linked Immunosorbent Assay Using Henipavirus-Receptor EphrinB2 and Monoclonal Antibodies for Detecting Nipah and Hendra Viruses. Zhu W; Smith G; Pickering B; Banadyga L; Yang M Viruses; 2024 May; 16(5):. PubMed ID: 38793674 [TBL] [Abstract][Full Text] [Related]
24. Broadly neutralizing antibody cocktails targeting Nipah virus and Hendra virus fusion glycoproteins. Dang HV; Cross RW; Borisevich V; Bornholdt ZA; West BR; Chan YP; Mire CE; Da Silva SC; Dimitrov AS; Yan L; Amaya M; Navaratnarajah CK; Zeitlin L; Geisbert TW; Broder CC; Veesler D Nat Struct Mol Biol; 2021 May; 28(5):426-434. PubMed ID: 33927387 [TBL] [Abstract][Full Text] [Related]
25. Nipah and Hendra Virus Glycoproteins Induce Comparable Homologous but Distinct Heterologous Fusion Phenotypes. Bradel-Tretheway BG; Zamora JLR; Stone JA; Liu Q; Li J; Aguilar HC J Virol; 2019 Jul; 93(13):. PubMed ID: 30971473 [TBL] [Abstract][Full Text] [Related]
26. Type I interferon signaling protects mice from lethal henipavirus infection. Dhondt KP; Mathieu C; Chalons M; Reynaud JM; Vallve A; Raoul H; Horvat B J Infect Dis; 2013 Jan; 207(1):142-51. PubMed ID: 23089589 [TBL] [Abstract][Full Text] [Related]
27. Single-dose live-attenuated Nipah virus vaccines confer complete protection by eliciting antibodies directed against surface glycoproteins. DeBuysscher BL; Scott D; Marzi A; Prescott J; Feldmann H Vaccine; 2014 May; 32(22):2637-44. PubMed ID: 24631094 [TBL] [Abstract][Full Text] [Related]
28. Potent Henipavirus Neutralization by Antibodies Recognizing Diverse Sites on Hendra and Nipah Virus Receptor Binding Protein. Dong J; Cross RW; Doyle MP; Kose N; Mousa JJ; Annand EJ; Borisevich V; Agans KN; Sutton R; Nargi R; Majedi M; Fenton KA; Reichard W; Bombardi RG; Geisbert TW; Crowe JE Cell; 2020 Dec; 183(6):1536-1550.e17. PubMed ID: 33306954 [TBL] [Abstract][Full Text] [Related]
29. A novel model of lethal Hendra virus infection in African green monkeys and the effectiveness of ribavirin treatment. Rockx B; Bossart KN; Feldmann F; Geisbert JB; Hickey AC; Brining D; Callison J; Safronetz D; Marzi A; Kercher L; Long D; Broder CC; Feldmann H; Geisbert TW J Virol; 2010 Oct; 84(19):9831-9. PubMed ID: 20660198 [TBL] [Abstract][Full Text] [Related]
30. A neutralization test for specific detection of Nipah virus antibodies using pseudotyped vesicular stomatitis virus expressing green fluorescent protein. Kaku Y; Noguchi A; Marsh GA; McEachern JA; Okutani A; Hotta K; Bazartseren B; Fukushi S; Broder CC; Yamada A; Inoue S; Wang LF J Virol Methods; 2009 Sep; 160(1-2):7-13. PubMed ID: 19433112 [TBL] [Abstract][Full Text] [Related]
31. Acute Hendra virus infection: Analysis of the pathogenesis and passive antibody protection in the hamster model. Guillaume V; Wong KT; Looi RY; Georges-Courbot MC; Barrot L; Buckland R; Wild TF; Horvat B Virology; 2009 May; 387(2):459-65. PubMed ID: 19328514 [TBL] [Abstract][Full Text] [Related]
32. Vaccination of ferrets with a recombinant G glycoprotein subunit vaccine provides protection against Nipah virus disease for over 12 months. Pallister JA; Klein R; Arkinstall R; Haining J; Long F; White JR; Payne J; Feng YR; Wang LF; Broder CC; Middleton D Virol J; 2013 Jul; 10():237. PubMed ID: 23867060 [TBL] [Abstract][Full Text] [Related]
33. A single-dose ChAdOx1-vectored vaccine provides complete protection against Nipah Bangladesh and Malaysia in Syrian golden hamsters. van Doremalen N; Lambe T; Sebastian S; Bushmaker T; Fischer R; Feldmann F; Haddock E; Letko M; Avanzato VA; Rissanen I; LaCasse R; Scott D; Bowden TA; Gilbert S; Munster V PLoS Negl Trop Dis; 2019 Jun; 13(6):e0007462. PubMed ID: 31170144 [TBL] [Abstract][Full Text] [Related]
34. Efficient reverse genetics reveals genetic determinants of budding and fusogenic differences between Nipah and Hendra viruses and enables real-time monitoring of viral spread in small animal models of henipavirus infection. Yun T; Park A; Hill TE; Pernet O; Beaty SM; Juelich TL; Smith JK; Zhang L; Wang YE; Vigant F; Gao J; Wu P; Lee B; Freiberg AN J Virol; 2015 Jan; 89(2):1242-53. PubMed ID: 25392218 [TBL] [Abstract][Full Text] [Related]
35. Exceptionally potent cross-reactive neutralization of Nipah and Hendra viruses by a human monoclonal antibody. Zhu Z; Bossart KN; Bishop KA; Crameri G; Dimitrov AS; McEachern JA; Feng Y; Middleton D; Wang LF; Broder CC; Dimitrov DS J Infect Dis; 2008 Mar; 197(6):846-53. PubMed ID: 18271743 [TBL] [Abstract][Full Text] [Related]
36. Virology. A henipavirus vaccine in sight. von Messling V; Cattaneo R Science; 2012 Aug; 337(6095):651-2. PubMed ID: 22879489 [No Abstract] [Full Text] [Related]
37. A neutralizing human monoclonal antibody protects against lethal disease in a new ferret model of acute nipah virus infection. Bossart KN; Zhu Z; Middleton D; Klippel J; Crameri G; Bingham J; McEachern JA; Green D; Hancock TJ; Chan YP; Hickey AC; Dimitrov DS; Wang LF; Broder CC PLoS Pathog; 2009 Oct; 5(10):e1000642. PubMed ID: 19888339 [TBL] [Abstract][Full Text] [Related]